Messaritakis, I <br/><br/>
Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  02 2017 
 - 16-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2016.12.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Biomarkers, Tumor--metabolism<br/>CD56 Antigen--immunology<br/>DNA-Binding Proteins--immunology<br/>Female<br/>Humans<br/>Indazoles<br/>Leukocyte Common Antigens--immunology<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplastic Cells, Circulating--drug effects<br/>Non-Randomized Controlled Trials as Topic<br/>Pyrimidines--administration & dosage<br/>Small Cell Lung Carcinoma--drug therapy<br/>Sulfonamides--administration & dosage<br/>Transcription Factors<br/>Vascular Endothelial Growth Factor Receptor-2--immunology